Literature DB >> 24182857

Biomarkers and updates on pediatrics lupus nephritis.

Michael Bennett1, Hermine I Brunner.   

Abstract

Lupus nephritis is a common complication of systemic lupus erythematosus in children and adolescents. This article reviews the clinical relevance of lupus nephritis and its current treatment. The reader is introduced to novel biomarkers that are expected to improve the management of lupus nephritis in the future, and support the testing of novel medication regimens.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Childhood-onset SLE; Lupus nephritis; Systemic lupus erythematosus; Treatment

Mesh：

Substances：

Year:  2013        PMID： 24182857      PMCID： PMC4980821          DOI： 10.1016/j.rdc.2013.05.001

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  146 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes.

Authors:  Norihiko Sakai; Takashi Wada; Kengo Furuichi; Kazuaki Shimizu; Satoshi Kokubo; Akinori Hara; Junya Yamahana; Toshiya Okumura; Kouji Matsushima; Hitoshi Yokoyama; Shuichi Kaneko
Journal:  J Leukoc Biol       Date:  2006-01-13       Impact factor: 4.962

3.  Belimumab for systemic lupus erythematosus.

Authors:  Neeraj Dhaun; David C Kluth
Journal:  Lancet       Date:  2011-06-18       Impact factor: 79.321

4.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2004-12

Review 5.  Treatment for lupus nephritis.

Authors:  Lorna Henderson; Philip Masson; Jonathan C Craig; Robert S Flanc; Matthew A Roberts; Giovanni F M Strippoli; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

6.  Factors associated with poor outcomes in patients with lupus nephritis.

Authors:  G Contreras; V Pardo; C Cely; E Borja; A Hurtado; C De La Cuesta; K Iqbal; O Lenz; A Asif; N Nahar; B Leclerq; C Leon; I Schulman; F Ramirez-Seijas; A Paredes; A Cepero; T Khan; F Pachon; E Tozman; G Barreto; D Hoffman; M Almeida Suarez; J C Busse; M Esquenazi; A Esquenazi; L Garcia Mayol; H Garcia Estrada
Journal:  Lupus       Date:  2005       Impact factor: 2.911

Review 7.  Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden.

Authors:  N Danchenko; J A Satia; M S Anthony
Journal:  Lupus       Date:  2006       Impact factor: 2.911

8.  Cost of treatment of childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Tina M Sherrard; Marisa S Klein-Gitelman
Journal:  Arthritis Rheum       Date:  2006-04-15

9.  Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.

Authors:  Chi Chiu Mok; King Yee Ying; Sydney Tang; Chung Ying Leung; Ka Wing Lee; Woon Leung Ng; Raymond Woon Sing Wong; Chak Sing Lau
Journal:  Arthritis Rheum       Date:  2004-08

10.  Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Authors:  Susan Manzi; Jorge Sánchez-Guerrero; Joan T Merrill; Richard Furie; Dafna Gladman; Sandra V Navarra; Ellen M Ginzler; David P D'Cruz; Andrea Doria; Simon Cooper; Z John Zhong; Douglas Hough; William Freimuth; Michelle A Petri
Journal:  Ann Rheum Dis       Date:  2012-05-01       Impact factor: 19.103
View more
  17 in total

1.  Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study.

Authors:  Valentina Živković; Tatjana Cvetković; Branka Mitić; Bojana Stamenković; Sonja Stojanović; Biljana Radovanović-Dinić; Vladimir Jurišić
Journal:  Rheumatol Int       Date:  2017-11-27       Impact factor: 2.631

2.  Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity.

Authors:  Jessica L Turnier; Hermine I Brunner; Michael Bennett; Ashwaq Aleed; Gaurav Gulati; Wendy D Haffey; Sherry Thornton; Michael Wagner; Prasad Devarajan; David Witte; Kenneth D Greis; Bruce Aronow
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

3.  Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults.

Authors:  Hermine I Brunner; Michael R Bennett; Gaurav Gulati; Khalid Abulaban; Marisa S Klein-Gitelman; Stacy P Ardoin; Lori B Tucker; Kelly A Rouster-Stevens; David Witte; Jun Ying; Prasad Devarajan
Journal:  J Rheumatol       Date:  2017-06-15       Impact factor: 4.666

4.  Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Gaurav Gulati; Marisa S Klein-Gitelman; Kelly A Rouster-Stevens; Lori Tucker; Stacey P Ardoin; Karen B Onel; Rylie Mainville; Jessica Turnier; Pinar Ozge Avar Aydin; David Witte; Bin Huang; Michael R Bennett; Prasad Devarajan
Journal:  Pediatr Nephrol       Date:  2018-08-29       Impact factor: 3.714

Review 5.  Advances in biomarkers for paediatric rheumatic diseases.

Authors:  Alessandro Consolaro; Giulia C Varnier; Alberto Martini; Angelo Ravelli
Journal:  Nat Rev Rheumatol       Date:  2014-12-16       Impact factor: 20.543

6.  Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systematic lupus erythematosus.

Authors:  Quentin Beaulieu; Daolun Zhang; Isabelle Melki; Véronique Baudouin; Lauriane Goldwirst; Jean-Baptiste Woillard; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2022-03-16       Impact factor: 2.953

7.  Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Rina Mina; Khalid Abulaban; Marisa S Klein-Gitelman; Barbara A Eberhard; Stacy P Ardoin; Nora Singer; Karen Onel; Lori Tucker; Kathleen O'neil; Tracey Wright; Elizabeth Brooks; Kelly Rouster-Stevens; Lawrence Jung; Lisa Imundo; Brad Rovin; David Witte; Jun Ying; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-02       Impact factor: 4.794

8.  Complement Deficiencies Result in Surrogate Pathways of Complement Activation in Novel Polygenic Lupus-like Models of Kidney Injury.

Authors:  Sladjana Skopelja-Gardner; Lucrezia Colonna; Payton Hermanson; Xizhang Sun; Lena Tanaka; Joyce Tai; Yenly Nguyen; Jessica M Snyder; Charles E Alpers; Kelly L Hudkins; David J Salant; YuFeng Peng; Keith B Elkon
Journal:  J Immunol       Date:  2020-04-01       Impact factor: 5.422

9.  Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus.

Authors:  D James Haddon; Vivian K Diep; Jordan V Price; Cindy Limb; Paul J Utz; Imelda Balboni
Journal:  Arthritis Res Ther       Date:  2015-06-17       Impact factor: 5.156

10.  Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity.

Authors:  Ellen M Cody; Michael R Bennett; Gaurav Gulati; Qing Ma; Mekibib Altaye; Prasad Devarajan; Hermine I Brunner
Journal:  Kidney Int Rep       Date:  2021-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.